Lisata Therapeutics (LSTA) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lisata Therapeutics (LSTA) has outperformed Pluri (PLUR) over the past year, losing 52.6% versus a loss of 75.5%. Over five years, LSTA leads with a -93.4% price change compared with -95.2% for PLUR. Lisata Therapeutics is the larger company by market cap ($13.0 million vs $12.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LSTA | PLUR |
|---|---|---|
| Share price | $1.20 | $1.00 |
| Market cap | $12.96M | $12.61M |
| 1-day change | +2.56% | -3.85% |
| YTD return | -35.48% | -66.56% |
| 1-year return | -52.57% | -75.49% |
| 5-year return | -93.44% | -95.23% |
| EPS (TTM) | $-1.64 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $4.87 |
| 52-week low | $0.99 | $0.85 |
| Distance from 52-week high | -76.33% | -79.47% |
| Analyst consensus | none | — |
| Average volume | 291.91K | 25.99K |
| Shares outstanding | 10.80M | 12.61M |
| Employees | 21 | 92 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LSTA has outperformed PLUR by 22.9 percentage points over the past year.
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Healthcare · Biotechnology · 21 employees
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Healthcare · Biotechnology · 92 employees
LSTA vs PLUR FAQ
Which is bigger, Lisata Therapeutics or Pluri?
Lisata Therapeutics (LSTA) is larger, with a market capitalization of $12.96M compared with $12.61M for Pluri (PLUR).
Which stock has performed better over the past year, LSTA or PLUR?
LSTA returned -52.57% over the past 12 months, compared with -75.49% for PLUR (price return, excluding dividends). Past performance does not predict future results.
Are Lisata Therapeutics and Pluri in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.